RedHill Biopharma Ltd. (RDHL) Form 6-K — Nov 2, 2026
RedHill Biopharma announced that two independent microbiology labs, led by Professor Tim Bull (City St George's University of London) and Professor Irene Grant (Queen's University Belfast), confirmed RHB-204's MAP-killing effect and comparability to RHB-104 in in vitro studies. The data support development of RHB-204, a next-generation formulation of RHB-104, for MAP-related Crohn's disease. RHB-104 previously met its Phase 3 primary endpoint, showing a 64% efficacy improvement over standard of care alone (p = 0.0048). RHB-204 is Phase 2-ready, patent-protected through 2041, and holds FDA Fast Track, Orphan Drug, QIDP and EU Orphan designations.
Key figures
- Cd market cagr
- 3.87%
- Cd market size 2033
- $19.1 billion
- Pill burden reduction
- 40%
- Anti tnf nonresponse rate
- up to 40%
- Patent protection through
- 2041
- Rhb104 phase3 efficacy improvement
- 64% more effective than SoC alone (p = 0.0048)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.